A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Napabucasin (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 30 Jun 2017 Results from combination arm of napabucasin with gemcitabine and nab-paclitaxel (n=66) presented at the European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer 2017, according to a Boston Biomedical media release.
    • 30 Jun 2017 Results from combination arm of napabucasin with gemcitabine and nab-paclitaxel (n=66) published in a Boston Biomedical media release.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top